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OBJECTIVE — To determine the association of TRIB3 Q84R polymorphism with metabolic
syndrome (MetS) and carotid atherosclerosis.
RESEARCH DESIGN AND METHODS — A case-control study enrolled 513 Chinese
subjects in three groups: control, MetS, and obese. The functional TRIB3 Q84R polymorphism
was genotyped among subjects undergoing carotid ultrasonography. The clinical and biochem-
ical characteristics were determined.
RESULTS — For individuals with the TRIB3 R84 allele, the odds ratio for developing MetS
was 2.349 (P  0.018), abdominal obesity 2.351 (P  0.012), hypertriglyceridemia 2.314 (P 
0.00003),andinsulinresistance1.697(P0.023).Likewise,theoddsratioforindividualswith
the TRIB3 R84 allele to develop thickened intima-media thickness was 2.208 (P  0.040).
CONCLUSIONS — Individuals with the functional TRIB3 Q84R polymorphism are at risk
for MetS. The TRIB3 R84 allele especially predisposes to carotid atherosclerosis in part through
the effects of abdominal obesity, hypertriglyceridemia, and insulin resistance.
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M
etabolic syndrome (MetS) is a
powerful and prevalent predictor
of cardiovascular events (1,2). In-
sulin resistance is recognized as the trig-
gering factor of MetS. The TRIB3 gene,
located on chromosome 20p13, has been
implicated in insulin resistance (3). A
TRIB3 Q84R polymorphism has also re-
cently been associated with early-onset
type 2 diabetes (4). This polymorphism
mayidentifyindividualsatriskforinsulin
resistance and related cardiovascular risk
(5). Whether the TRIB3 Q84R polymor-
phism increases the risk for MetS and ca-
rotid atherosclerosis remains to be
established.
RESEARCH DESIGN AND
METHODS— Atotalof513unrelated
Chinese subjects aged 24–85 years were
recruited from the Qilu Hospital of Shan-
dong University: 217 subjects with MetS,
deﬁned by the International Diabetes
Federation(6);200subjects(controlsub-
jects) without any abnormality; and 96
obese-alone subjects. Written informed
consent was obtained from all subjects,
and procedures were approved by the in-
stitutional ethics committees.
The clinical and biochemical charac-
teristics of the subjects were determined.
Insulin resistance was assessed by the ho-
meostasismodelassessmentequation(7).
Genotyping of the TRIB3 R84 variant was
as previously described (5).
B-mode ultrasonography of the ca-
rotid arteries was performed by one
trained clinical technician. Both the
right and left common carotid arteries
wereexamined.Intima-mediathickness
(IMT) of the common and internal ca-
rotid arteries and bifurcations were
measured according to the Asympto-
matic Carotid Artery Plaque Study
(ACAPS) protocol (8). (For details, see
the online-only appendix available at
http://care.
diabetesjournals.org/cgi/content/full/dc09-
0061/DC1.)
Statistical analysis
The Kolmogorov-Smirnov test was used
to test for normal distribution. Normally
distributeddataarepresentedasmeans
SD. Continuous variables were compared
among groups by one-way ANOVA with
post hoc least-signiﬁcant differences t test
or Kruskal-Wallis H test. The 
2 test was
used to analyze the associations between
categorical variables. Multivariate regres-
sion analysis of risk factors was per-
formed,withoddsratios(ORs)(95%CIs)
shown.Multiplelinearregressionanalysis
wasusedtoevaluatethecontributionofrisk
factors. The correlation between two vari-
ables was assessed by Pearson or Spearman
correlation analysis. A P value 0.05 was
considered signiﬁcant. Analyses involved
SPSS v. 13.0 (SPSS, Chicago, IL).
RESULTS— Genotyping was success-
ful in 513 case subjects. The TRIB3 Q84R
polymorphism genotypes were in Hardy-
Weinberg equilibrium. The clinical and
biochemicalcharacteristicsofthesubjects
by TRIB3 genotype in the MetS group are
in Table 1. Subjects with the RR84 geno-
type had higher waist-to-hip ratio and to-
tal cholesterol, triglyceride, and LDL
cholesterol levels but lower HDL choles-
terol levels than individuals with the
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the Key Laboratory of Cardiovascular Remodeling and Function Research Chinese Ministry of Edu-
cation and Chinese Ministry of Public Health, Department of Cardiology, Qilu Hospital of Shandong
University, Ji’nan, People’s Republic of China.
Corresponding authors: Ming Zhong, zhongmingzm@gmail.com, and Wei Zhang, zhangweisdu@
gmail.com.
Received 13 January 2009 and accepted 13 April 2009.
Published ahead of print at http://care.diabetesjournals.org on 23 April 2009. DOI: 10.2337/dc09-0061.
H.G. and Z.W. contributed equally to this study.
J.L. is currently with the Cancer Epigenetics Laboratory, State Key Laboratory in Oncology in South China,
Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, People’s Republic of
China.
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cardiovascular and Metabolic Risk
BRIEF REPORT
DIABETES CARE, VOLUME 32, NUMBER 7, JULY 2009 1311QQ84 genotype (P  0.05 for all). Sub-
jects with different Q84R genotypes did
not differ in age, sex, BMI, waist circum-
ference, blood pressure, fasting blood
glucose, insulin, and homeostasis model
assessment of insulin resistance (Table 1)
or medication for diabetes or hyperten-
sion. The genetic and biochemical results
from MetS and control groups suggest an
association of the TRIB3 Q84R variant
with metabolism in humans (see supple-
mental Table A1 in the online appendix).
TRIB3 Q84R genotype was associated
with MetS (P  0.021), and stepwise re-
gression analysis revealed the risk factors
for MetS as being the TRIB3 R84 allele
(OR 2.349 [95% CI 1.156–4.775]; P 
0.018) and smoking (3.130 [1.172–
8.358]; P  0.023).
After dichotomization, the TRIB3
Q84R genotype was associated with ab-
dominal obesity (P  0.048). Further-
more, stepwise multivariate regression
analysis revealed the risk factors for ab-
dominal obesity as being the TRIB3 R84
allele (OR 2.351 [95% CI 1.210–4.568];
P  0.012), sex (1.113 [1.015–1.220];
P0.023),andtriglyceridelevel(16.869
[1.389–204.808]; P  0.027).
TRIB3 Q84R genotype was associated
with hypertriglyceridemia (P  0.005).
Furthermore, stepwise multivariate re-
gression analysis revealed the risk factors
for hypertriglyceridemia as being the
TRIB3 R84 allele (2.314 [1.494–3.585];
P  0.00003), waist-to-hip ratio
(12,007.348 [18.463–7,808,726]; P 
0.004), systolic blood pressure (1.029
[1.007- 1.051]; P  0.008), fasting blood
glucose (1.769 [1.276–2.453]; P 
0.001), and insulin level (1.205 [1.080–
1.344]; P  0.001).
Unexpectedly, fasting blood glucose
and fasting insulin level had no associa-
tionwiththeTRIB3Q84Rpolymorphism.
However, the TRIB3 Q84R genotype was
associated with insulin resistance (P 
0.040). Stepwise univariate regression
analysis demonstrated the TRIB3 R84 al-
lele as a risk factor for insulin resistance
(1.697[1.076–2.677];P0.023).Thus,
carriers of the TRIB3 R84 allele are more
susceptibletoMetS,especiallyforabdom-
inal obesity, hypertriglyceridemia, and
insulin resistance.
Accordingly, whether the TRIB3 R84
allele was associated with atherosclerosis
was investigated. Subjects with the RR84
genotype had signiﬁcantly higher mean
and maximal IMT than individuals with
the QQ84 and QR84 genotypes (P 
0.001 for both). We found risk factors for
thickened IMT as being the TRIB3 R84
allele (2.208 [1.036–4.709]; P  0.040),
age (1.137 [1.082–1.195]; P  8.3 
10
10), systolic blood pressure (1.025
[1.009–1.041];P0.002),andwaist-to-
hip ratio (878.411 [2.311–333,869.6];
P0.025).Moreover,multivariatelinear
regression showed that the TRIB3 Q84R
polymorphism contributed, although
slightly, to the variation in IMT (
0.099,P0.026,supplementalTableA2
in the online appendix).
CONCLUSIONS — This is the ﬁrst
large study that comprehensively identi-
ﬁes the TRIB3 Q84R polymorphism as a
candidate single nucleotide polymor-
phism for MetS and carotid atherosclero-
sis. We demonstrated that TRIB3 R84
allele carriers are at increased risk for
MetS and carotid atherosclerosis because
they are more susceptible to abdominal
obesity, hypertriglyceridemia, and insu-
lin resistance.
Therefore, TRIB3 is speculated to
contribute to MetS via alteration of glu-
coseandfat,withinsulinplayingapivotal
role. That TRIB3 R84 was also located on
chromosome 20p1 further conﬁrms the
association because it is generally as-
sumed that susceptibility loci of obesity
and type 2 diabetes were on chromosome
20p (9,10). Based on that, it implies that
TRIB3 contributes to MetS via alteration
of glucose and fat. However, The TRIB3
Q84Rpolymorphismwasnotincludedin
the gene chips used by recent type 2 dia-
betes genome-wide association studies to
clarify its contribution (11).
Extensive evidence (1,2,12) shows
that the presence of MetS increases the
risk of atherosclerosis. Here, we showed
that the TRIB3 Q84R genotype facilitates
Table 1—Clinical and biochemical characteristics of subjects by TRIB3 Q84R genotype in MetS group
QQ84
(n  125) QR84 (n  79) RR84 (n  13)
PP *
vs. QQ84
group
vs. QR84
group
vs. QQ84
group
vs. QR84
group
Sex (male/female) 51/74 39/40 9/4 0.076 0.237
Age (years) 55.15  9.14 54.71  9.84 56.85  6.40 0.532 0.442
BMI (kg/m
2) 28.95  4.31 28.80  3.90 29.61  2.80 0.581 0.508
Systolic blood pressure (mmHg) 152.19  22.11 148.10  20.72 156.85  28.47 0.471 0.187
Diastolic blood pressure (mmHg) 94.14  14.00 93.35  13.74 91.62  16.05 0.539 0.681
Waist circumference (cm) 98.01  9.73 97.37  10.42 101.31  8.81 0.259 0.188
Waist-to-hip ratio 0.93  0.06 0.93  0.06 0.96  0.04 0.041 0.041
Total cholesterol (mmol/l) 5.29  1.29 5.48  1.10 6.03  0.87 0.038 0.130 0.056 0.198
Triglycerides (mmol/l) 2.04  0.92 2.57  1.64 2.77  1.24 0.047 0.587 0.008 0.847
HDL cholesterol (mmol/l) 1.25  0.30 1.24  0.42 1.04  0.19 0.034 0.047 0.077 0.063
LDL cholesterol (mmol/l) 3.49  0.94 3.58  0.96 4.06  1.07 0.044 0.098 0.033 0.088
Fasting blood glucose (mmol/l) 6.69  2.41 6.64  2.71 6.13  2.47 0.446 0.501
Insulin (U/ml) 20.47  10.76 20.04  9.67 19.23  14.68 0.694 0.802
HOMA-IR 6.30  4.71 5.84  3.22 5.24  4.50 0.389 0.639
Normal IMT 80 41 2 0.001 0.017
Mean IMT (mm) 0.75  0.15 0.76  0.18 0.95  0.18 0.00007 0.0002
Maximum IMT (mm) 1.07  0.69 1.23  0.88 2.44  1.17 0.00000005 0.000002
Data are means  SD unless otherwise indicated. *P, adjusted for waist-to-hip ratio, sex, age, and smoking. HOMA-IR, homeostasis model assessment for insulin
resistance.
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Because we have found that TRIB3 R84
allele carriers are at increased risk for ab-
dominal obesity, hypertriglyceridemia,
and insulin resistance, all of which have
beenvalidatedasindependentriskfactors
for carotid atherosclerosis (13–15), these
features are the variant’s link to carotid
atherosclerosis.
In summary, the current ﬁndings
provide direct evidence that individuals
withtheRR84aremoresusceptibletoab-
dominal obesity, hypertriglyceridemia,
andinsulinresistance.Therefore,theyare
at risk for MetS and predisposed to ca-
rotid atherosclerosis.
Acknowledgments— This work was sup-
ported by research grants from the Key Tech-
nologies R&D Program of Shandong Province
(2006GG2202020), the National Natural Sci-
ence Foundation of China (30670874,
30570748, and 30871038), and the National
Basic Research Program of China (973 Pro-
gram, Grant 2009CB521904).
No potential conﬂicts of interest relevant to
this article were reported.
References
1. Isomaa B, Almgren P, Tuomi T, Forse ´nB,
Lahti K, Nisse ´n M, Taskinen MR, Groop
L. Cardiovascular morbidity and mortal-
ity associated with the metabolic syn-
drome. Diabetes Care 2001;24:683–689
2. Lakka HM, Laaksonen DE, Lakka TA, Ni-
skanen LK, Kumpusalo E, Tuomilehto J,
Salonen JT. The metabolic syndrome and
total and cardiovascular disease mortality
in middle-aged men. JAMA 2002;288:
2709–2716
3. Du K, Herzig S, Kulkarni RN, Montminy
M. TRB3: a tribbles homolog that inhibits
Akt/PKBactivationbyinsulininliver.Sci-
ence 2003;300:1574–1577
4. Prudente S, Scarpelli D, Chandalia M,
Zhang YY, Morini E, Del Guerra S, Perti-
coneF,LiR,PowersC,AndreozziF,Mar-
chettiP,DallapiccolaB,AbateN,DoriaA,
Sesti G, Trischitta V. The TRIB3 Q84R
polymorphism and risk of early-onset
type 2 diabetes. J Clin Endocrinol Metab
2009;94:190–196
5. Prudente S, Hribal ML, Flex E, Turchi F,
Morini E, De Cosmo S, Bacci S, Tassi V,
Cardellini M, Lauro R, Sesti G, Dallapic-
cola B, Trischitta V. The functional Q84R
polymorphism of mammalian Tribbles
homolog TRB3 is associated with insulin
resistance and related cardiovascular risk
in Caucasians from Italy. Diabetes 2005;
54:2807–2811
6. Alberti KG, Zimmet P, Shaw J, the IDF
Epidemiology Task Force Consensus
Group. The metabolic syndrome: a new
worldwide deﬁnition. Lancet 2005;366:
1059–1062
7. Matthews DR, Hosker JP, Rudenski AS,
Naylor BA, Treacher DF, Turner RC. Ho-
meostasis model assessment: insulin re-
sistance and beta-cell function from
fasting plasma glucose and insulin con-
centrations in man. Diabetologia 1985;
28:412–419
8. Espeland MA, Craven TE, Riley WA,
Corson J, Romont A, Furberg CD. Reli-
ability of longitudinal ultrasonographic
measurementsofcarotidintimal-medial
thicknesses: Asymptomatic Carotid Ar-
tery Progression Study Research Group.
Stroke 1996;27:480–485
9. Ghosh S, Watanabe RM, Hauser ER, Valle
T, Magnuson VL, Erdos MR, Langefeld
CD, Balow J Jr, Ally DS, Kohtamaki K,
Chines P, Birznieks G, Kaleta HS, Musick
A, Te C, Tannenbaum J, Eldridge W, Sha-
piro S, Martin C, Witt A, So A, Chang J,
Shurtleff B, Porter R, Kudelko K, Unni A,
Segal L, Sharaf R, Blaschak-Harvan J,
Eriksson J, Tenkula T, Vidgren G, Ehn-
holm C, Tuomilehto-Wolf E, Hagopian
W, Buchanan TA, Tuomilehto J, Bergman
RN, Collins FS, Boehnke M. Type 2 dia-
betes: evidence for linkage on chromo-
some 20 in 716 Finnish affected sib pairs.
Proc Natl Acad SciUSA1999;96:2198–
2203
10. VionnetN,HaniEH,DupontS,GallinaS,
FranckeS,DotteS,DeMatosF,DurandE,
Lepre ˆtre F, Lecoeur C, Gallina P, Zekiri L,
Dina C, Froguel P. Genomewide search
for type 2 diabetes-susceptibility genes in
French whites: evidence for a novel sus-
ceptibility locus for early-onset diabetes
on chromosome 3q27-qter and indepen-
dent replication of a type 2-diabetes locus
on chromosome 1q21–q24. Am J Hum
Genet 2000;67:1470–1480
11. Zeggini E, Scott LJ, Saxena R, Voight BF,
MarchiniJL,HuT,deBakkerPI,Abecasis
GR, Almgren P, Andersen G, Ardlie K,
Bostro ¨m KB, Bergman RN, Bonnycastle
LL, Borch-Johnsen K, Burtt NP, Chen H,
Chines PS, Daly MJ, Deodhar P, Ding CJ,
Doney AS, Duren WL, Elliott KS, Erdos
MR, Frayling TM, Freathy RM, Gianniny
L, Grallert H, Grarup N, Groves CJ,
Guiducci C, Hansen T, Herder C, Hitman
GA, Hughes TE, Isomaa B, Jackson AU,
Jørgensen T, Kong A, Kubalanza K, Kuru-
villaFG,KuusistoJ,LangenbergC,Lango
H, Lauritzen T, Li Y, Lindgren CM, Lys-
senko V, Marvelle AF, Meisinger C,
Midthjell K, Mohlke KL, Morken MA,
Morris AD, Narisu N, Nilsson P, Owen
KR, Palmer CN, Payne F, Perry JR, Pet-
tersen E, Platou C, Prokopenko I, Qi L,
QinL,RaynerNW,ReesM,RoixJJ,Sand-
baek A, Shields B, Sjo ¨gren M, Steinthors-
dottir V, Stringham HM, Swift AJ,
Thorleifsson G, Thorsteinsdottir U,
Timpson NJ, Tuomi T, Tuomilehto J,
Walker M, Watanabe RM, Weedon MN,
Willer CJ, Wellcome Trust Case Control
Consortium, Illig T, Hveem K, Hu FB,
Laakso M, Stefansson K, Pedersen O,
Wareham NJ, Barroso I, Hattersley AT,
Collins FS, Groop L, McCarthy MI, Boe-
hnke M, Altshuler D. Meta-analysis of ge-
nome-wide association data and large-
scale replication identiﬁes additional
susceptibility loci for type 2 diabetes. Nat
Genet 2008;40:638–645
12. Grundy SM, Cleeman JI, Daniels SR, Do-
nato KA, Eckel RH, Franklin BA, Gordon
DJ, Krauss RM, Savage PJ, Smith SC Jr,
Spertus JA, Costa F, the American Heart
Association, National Heart, Lung, and
Blood Institute. Diagnosis and manage-
ment of the metabolic syndrome: an
American Heart Association/National
Heart,Lung,andBloodInstituteScientiﬁc
Statement. Circulation 2005;112:2735-
2752
13. Kozakova M, Palombo C, Paterni M,
Anderwald CH, Konrad T, Colgan MP,
Flyvbjerg A, Dekker J. Relationship be-
tween insulin sensitivity cardiovascular
risk investigators. body composition and
common carotid artery remodeling in a
healthy population. J Clin Endocrinol
Metab 2008;93:3325–3332
14. Teno S, Uto Y, Nagashima H, Endoh Y,
Iwamoto Y, Omori Y, Takizawa T. Asso-
ciation of postprandial hypertriglyceride-
mia and carotid intima-media thickness
in patients with type 2 diabetes. Diabetes
Care 2000;23:1401–1406
15. Sourij H, Schmoelzer I, Dittrich P,
Paulweber B, Iglseder B, Wascher TC. In-
sulin resistance as a risk factor for carotid
atherosclerosis: a comparison of the ho-
meostasismodelassessmentandtheshort
insulin tolerance test. Stroke 2008;39:
1349–1351
Gong and Associates
DIABETES CARE, VOLUME 32, NUMBER 7, JULY 2009 1313